Continuing the conversation in growth hormone disorders – how do we progress towards personalized medicine for patients with acromegaly?
Stay up to date with the latest developments in the diagnosis, management and treatment of patients with acromegaly with our expert summary from the European Congress of Endocrinology (ECE) in Lyon, France, 18–21 May 2019. Part 1: Watch internationally renowned expert Prof. John Wass review key data from ECE2019 Part 2: Choose from leading experts who discuss what the data findings mean for global and regional practice
- Interpret the latest information and guidance about the need for early diagnosis and monitoring of acromegaly
- Recall the most recent data around patient and disease characteristics, including the importance of recognizing comorbidities, in order to select the optimal treatment strategy for each individual patient with acromegaly
- Recognize the role of medical treatment options for acromegaly and best practice for patient management using a multidisciplinary team approach
Continuing the conversation in paediatric endocrinology – how do the latest advances in understanding biology translate to improved patient care?
Stay up to date with the latest developments in the biology, diagnosis and treatment of paediatric patients with growth hormone disorders with our touchCONGRESS Webinar and Expert Interviews from the European Society for Paediatric Endocrinology (ESPE) Congress in Vienna, Austria, 19–21 September 2019. Part 1: Watch internationally renowned expert Prof. Martin Savage review key data from ESPE 2019 Part 2: Choose from leading experts who discuss what the data finding mean for global and reginal practice
- Recall the latest advances in understanding the biology of paediatric growth disorders
- Interpret the latest data for the diagnosis and management of paediatric growth disorders and their impact on daily clinical practice
- Recognize the importance of personalized medicine on clinical outcomes
Arun Sanyal, EASL ILC 2021: Icosabutate ICONA Trial in NASH
In Part 2, we speak with Prof. Arun Sanyal (Virginia Commonwealth University, Richmond, VA, USA) about the interim analysis from the ICONA trial (NCT04052516) which is designed to investigate icosabutate as a potential therapeutic approach to address liver- and cardiovascular-related morbidity and mortality in patients with NASH. His abstract entitled ‘Icosabutate, a novel structurally engineered […]
Claudia Fox, ENDO 2021: Exenatide for Weight Loss Maintenance in Adolescents
We were delighted to talk to Professor Claudia Fox (University of Minnesota, Minneapolis, MN, US) around the use of exenatide for weight loss maintenance among adolescents with severe obesity. ‘Once-Weekly Exenatide Enhances Weight Loss Maintenance in Adolescents with Severe Obesity: A Randomized, Placebo-Controlled Trial.‘ (PRESENTATION NUMBER: OR02-4) was presented at the ENDO 2021 Virtual Annual […]
Domenica M. Rubino, ENDO 2021: Findings from the STEP 4 Study
It was a pleasure to talk to Dr Domenica Rubino (Washington Center for Weight Management and Research, Arlington, VA, US) around the effect of once-weekly semaglutide on weight loss maintenance in overweight or obese adults. ‘Weight Loss Maintenance With Once-Weekly Semaglutide 2.4 MG in Adults With Overweight or Obesity Reaching Maintenance Dose (STEP 4).‘ (PRESENTATION […]
Luca Valenti, NAFLD Summit 2021: The Latest Advances in NAFLD
TouchENDOCRINOLOGY joins Prof Luca Valenti (University of Milan, Italy) at the Digital NAFLD Summit 2021 to discuss his hopes for the conference and the most exciting new developments in the field of non-alcoholic fatty liver disease (NAFLD). Questions Could you give us an overview of the clinical spectrum of non-alcoholic fatty liver disease (NAFLD) and […]
Acromegaly Due to McCune–Albright Syndrome
US Endocrinology. 2020;16(1):47–50 DOI: https://doi.org/10.17925/USE.2020.16.1.47
McCune–Albright syndrome (MAS) is a genetic disorder first described by McCune1 and Albright2 in the 1930s as a triad of polyostotic fibrous dysplasia, café-au-lait spots, and precocious puberty (Figure 1). Since then, other hyperfunctioning endocrinopathies have been described in MAS, including hyperthyroidism, Cushing’s syndrome, hypophosphatemic osteomalacia, and acromegaly.3 Patients with MAS display mosaicism as the disease results […]
Pheochromocytoma Due to TMEM127 Mutation – The Importance of Genetic Testing for Clinical Decision
European Endocrinology. 2020;16(1):72-4
Catecholamine-secreting tumours that arise from chromaffin cells of the adrenal medulla and the sympathetic ganglia are respectively referred to as pheochromocytomas and paragangliomas. The term paraganglioma is also used for tumours derived from parasympathetic tissue in the head and neck, most of which do not produce catecholamines.1 The classic triad of symptoms in patients with […]
Diabetic Polyneuropathy – Advances in Diagnosis and Intervention Strategies
European Endocrinology. 2020;16(1):15–20
Diabetic polyneuropathy (DPN) is the most common microvascular complication of diabetes, affecting approximately 50% of all people with diabetes (type 1 diabetes [T1D] and type 2 diabetes [T2D]).1 DPN is a major cause of disability due to sensory loss, gait instability and fall‐related injuries,1–5 and is the strongest risk factor for diabetic foot ulceration and amputation.1–4 Up to […]
Cost Comparison of Flash Continuous Glucose Monitoring with Self-monitoring of Blood Glucose in Adults with Type 1 or Type 2 Diabetes Using Intensive Insulin—From a US Private Payer Perspective
US Endocrinology. 2020;16(1):24–30 DOI: https://doi.org/10.17925/USE.2020.16.1.24
Unmet needs for glucose monitoring in people with diabetes mellitus using intensive insulin Glucose monitoring is essential for people using intensive insulin to inform adjustments to the treatment and management of diabetes. Evidence suggests many people do not adhere to the recommended testing frequency with self-monitoring of blood glucose (SMBG). In the USA, it was […]
What promise do novel lipoprotein-lowering therapies hold for effectively reducing ASCVD risk? Perspectives from a multidisciplinary team
Select a discussion in the hub to watch our multidisciplinary faculty share their insights on how novel lipoprotein-lowering therapies can help to reduce ASCVD risk and what this may mean for patient care in the future.
Optimizing the management of gastroenteropancreatic neuroendocrine tumours
Watch leading experts explore how recent scientific and clinical advances may optimize the medical management of gastroenteropancreatic neuroendocrine tumours (GEP-NETs) in 2021, and beyond.
Diagnosis and Clinical Management of Long-chain Fatty-acid Oxidation Disorders: A Review
touchREVIEWS in Endocrinology. 2021;17(2):Online ahead of journal publication
Long-chain fatty-acid oxidation disorders (LC-FAODs) are pan-ethnic, autosomal recessive, inherited metabolic conditions causing disruption in the processing or transportation of fats into the mitochondria to perform beta oxidation.1 In normal metabolism, long-chain fatty acids are bound to carnitine within the cytosol of cells, and transported across the mitochondrial membranes. Within the mitochondria, they are then cleaved […]
Non-alcoholic Steatohepatitis: From Pathophysiology to Clinical Practice
touchREVIEWS in Endocrinology. 2021;1(2):Online ahead of journal publication
Non-alcoholic fatty liver disease (NAFLD) consists of non-alcoholic fatty liver (NAFL) and non-alcoholic steatohepatitis (NASH). It is unclear which specific patients progress from NAFL to NASH and, ultimately, to cirrhosis. However, there is general consensus that, for those patients who do progress to cirrhosis (fibrosis stage 4), there is an increased risk of liver-related complications […]
Congenital Adrenal Hyperplasia Due to 17-α-hydroxylase Deficiency: A Case Report
touchREVIEWS in Endocrinology. 2021;17(2): Online ahead of journal publication
Congenital adrenal hyperplasia is an innate error in the biosynthesis of adrenal steroids, which triggers a wide range of consequences based on the level of the enzyme blockade. A deficiency in the enzyme 21-α-hydroxylase is the most frequent cause, presenting with different degrees of virilization in women, and may or may not present with the […]
Controversies in Gestational Diabetes
touchREVIEWS in Endocrinology. 2021;17(2):Online ahead of journal publication.
Gestational diabetes mellitus (GDM), defined as hyperglycaemia identified after the first trimester of pregnancy that is not clearly overt diabetes, impacts approximately 7% of births in the USA; a percentage that has increased in parallel with the prevalence of both obesity and type 2 diabetes over the past 20 years.1–4 The impacts of GDM include hypertensive […]
Want To Know More About Our Journals?
Taking a balanced and practical view of the current clinical landscape in Endocrinology is at the heart of touchENDOCRINOLOGY and the journals we produce.
The European Endocrinology and US Endocrinology are free-to-access, peer reviewed journals that aim to provide balanced and objective articles relevant to the day-to-day clinical setting.
Journal articles and more to your inbox
Get the latest clinical insights from touchENDOCRINOLOGYSign me up!